Before 2022, OPDIVO, jointly developed by Ono Pharmaceutical and Bristol Myers Squibb, encountered significant headwinds in Japan's fiercely competitive oncology sector. The immunotherapy witnessed considerable market erosion as the KEYTRUDA vs OPDIVO rivalry intensified, with clinicians showing growing preference for Merck's KEYTRUDA across multiple treatment scenarios.
This competitive shift...
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek